Top Back to top

Practice patterns of holding and bridging therapy for mantle cell lymphoma patients in the CAR T-cell setting

Lymphoma Working Party (LWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
Holding & bridging therapy for MCL in CAR-T cell
Primary objective:
- Define standard practice for communication and patient referral among centers
- Describe holding strategies (therapy administered before leukapheresis)
- Describe bridging strategies (therapy administered after leukapheresis)
- Particular focus on targeted agents in the peri-CART setting:
- BTKi before and after CAR T-cell infusion
- Venetoclax before and after CAR T-cell infusion
Key inclusion criteria:
This study will focus on adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor; that is to say, patients who are candidates for brexu-cel therapy.
All EBMT member countries
Principal investigator:
Gloria Iacoboni, MD, PhD, Pere Barba, MD, PhD
EBMT Study coordinator:
Study coordinator email:
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Not applicable to surveys
Categories of personal data collected:
Not applicable to surveys
Recipients who may access the data:
Not applicable to surveys
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
Not applicable to surveys

Privacy notices

Article 6 lawful basis for processing personal data:
Not applicable to surveys
Article 9 basis for processing special category data:
Not applicable to surveys

Data Protection Impact Assessments

Rights available to individuals:
Data portability
Is a Data Protection Impact Assessment required?:
Not applicable to surveys
Retention Schedule (if possible):
Not applicable to surveys